Enalapril Richet en es it fr


Enalapril Richet Nombres de marca, Enalapril Richet Analogos

Enalapril Richet Marca los nombres de mezcla

  • Vaseretic (Enalapril Maleate + Hydrochlorothiazide)
  • Enalapril Richet Formula quimica


    Enalapril Richet RX enlace


    Enalapril Richet FDA hoja

    Enalapril_Richet FDA

    Enalapril Richet MSDS (hoja de seguridad de materiales)

    Enalapril Richet Sintesis de referencia

    A. Patchett et al., Nature 288, 280 (1980)

    Enalapril Richet Peso molecular

    376.447 g/mol

    Enalapril Richet Punto de fusion


    Enalapril Richet H2O Solubilidad


    Enalapril Richet Estado


    Enalapril Richet LogP


    Enalapril Richet Formas de dosificacion

    Tableta, inyección IV

    Enalapril Richet Indicacion

    Para el tratamiento de la hipertensión y la insuficiencia cardiaca. Se puede utilizar solo o en combinación con diuréticos tiazídicos.

    Enalapril Richet Farmacologia

    Enalapril, una enzima convertidora de la angiotensina (ECA), es un profármaco que, cuando se hidroliza por estarases a su enalaprilato activo, se utiliza para tratar la hipertensión y la insuficiencia cardiaca, para reducir la proteinuria y la enfermedad renal en pacientes con nefropatías, y para evitar accidente cerebrovascular, infarto de miocardio y muerte cardíaca en pacientes de alto riesgo. Enalapril y enalaprilato inhibir la enzima convertidora de angiotensina (ACE) en seres humanos y animales. La ECA es una peptidil dipeptidasa que cataliza la conversión de angiotensina I en la sustancia vasoconstrictora de la angiotensina II. La angiotensina II también estimula la aldosterona la secreción de la corteza suprarrenal.

    Enalapril Richet Absorcion


    Enalapril Richet Toxicidad


    Enalapril Richet Informacion de Pacientes

    Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

    Hypotension: Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

    All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician. Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACEinhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

    Enalapril Richet Organismos afectados

    Humanos y otros mamíferos